



US005656602A

United States Patent [19]

Tseng et al.

[11] Patent Number: **5,656,602**
[45] Date of Patent: **Aug. 12, 1997**

[54] PLA₂ INHIBITORY COMPOUNDS

[75] Inventors: **Albert Peng Sheng Tseng**, Epping;
Adam Inglis, Strathmore; **Kieran**
Scott, Waverley, all of Australia

[73] Assignee: **Garvan Institute of Medical**
Research, Darlinghurst, Australia

[21] Appl. No.: **170,360**

[22] PCT Filed: **Jul. 6, 1992**

[36] PCT No.: **PCT/AU92/00333**

§ 371 Date: **Mar. 3, 1994**

§ 102(e) Date: **Mar. 3, 1994**

[87] PCT Pub. No.: **WO93/01215**

PCT Pub. Date: **Jan. 21, 1993**

[30] Foreign Application Priority Data

Jul. 4, 1991 [AU] Australia PK7058

[51] Int. CL⁶ **A61K 38/00**; **C07K 7/00**

[52] U.S. Cl. **514/17**; **514/11**; **530/317**;
530/329; **530/330**

[58] Field of Search **530/317**, **329**,
530/330; **514/11**, **17**

[56] References Cited

U.S. PATENT DOCUMENTS

4,742,155 5/1988 Umezawa et al. 530/317
4,792,555 12/1988 McGregor et al. 514/255
4,895,931 1/1990 Okazaki et al. 530/326

FOREIGN PATENT DOCUMENTS

288965 4/1988 European Pat. Off. .
397679 6/1989 European Pat. Off. .

OTHER PUBLICATIONS

Merck Manual, Fifteenth Edition, Merck & Co., Rahway, NJ
(1987). See pp. 65-67.

Gardella, T. et al. (1991) Mutational analysis of the recep-
tor-activating region of human parathyroid hormone. *J.*
Biol. Chem. 266 (20), 13141-6. See abstract.

Tomatis, R. et al. (1978) Studies on trypsin inhibitors. Part
VIII. *Int. J. Pept. Protein Res.* 11, 269-281. See abstract.

Guggi, A. et al. (1976) Studies on trypsin inhibitors. Part IV.
Int. J. Pept. Protein Res. 8, 97-105. See abstract.

Baev, V. et al. (1978) Synthesis and biological activity of
luliberin and its analogs. *Bioorg. Khim.* 4(4), 489-99. See
abstract.

Stewart, F. (1969) Synthesis of peptide derivatives related to
evoldin *Aust. J. Chem.* 22(12), 2663-71. See abstract.

Biotechnology Newswatch, Aug. 1, 1994, pp. 1 and 4.

The Washington Post, Jan. 19, 1993, p. D3.

Cross, A. et al. (1993) Choice of bacteria in animal models
of sepsis. *Infection and Immunity* 61, 2741-2747. See entire
article.

Patent Abstracts of Japan No. J 63-255298(A) to Yaman-
ouchi.

Scott, et al., *Science*, vol. 250, pp. 1541-1546, Dec. 1990.

Kramer, et al., *J. Biol. Chem.*, vol. 264, pp. 5768-5775, Apr.
1989.

Bouchier, et al., *Biochem. Biophys. Acta*, vol. 1088, pp.
401-408, 1991.

Scott, et al., *Science*, vol. 250, pp. 1563-1566, Dec. 1990.

White et al., *Science*, vol. 250, pp. 1560-1563, Dec. 1990.

Seilheimer, et al., *J. Biol. Chem.* vol. 264, pp. 5335-5338,
Apr. 1989.

Johnson, et al., *Adv. Exp. Med. Biol.*; PLA 2 Role and
Function in Inflammation, P. Y. K. Wong ed., Plenum Press,
pp. 17-34, 1990.

Renetseder, et al., *J. Biol. Chem.*, vol. 260, pp.
11627-11634, Sep. 1985.

Primary Examiner—Michael P. Woodward

Assistant Examiner—Benet Prickril

Attorney, Agent, or Firm—Rothwell, Figg, Ernst & Kurz

[57] ABSTRACT

The present invention provides peptides and compounds
which inhibit the enzyme activity of Type II phospholipases
A₂. The preferred compounds are pentapeptides. Where the
phospholipase is human Type II phospholipase A₂ the pre-
ferred peptides are FLSYK and KFLSY.

9 Claims, 7 Drawing Sheets

Exon 2:		1	10	20	30	40
PORCINE	I	<u>ALWQFRSMIKCAIPGSHPLMDFNNYGCYCGLGGSGTPVDELDR</u>				
RAT	I	<u>AVWQFRNMIKCTIPGSDPFREYNNYGCYCGLGGSGTPVDDLDR</u>				
HUMAN	I	<u>AVWQFRKMIKCVIPGSDPFLEYNNYGCYCGLGGSGTPVDELDK</u>				
		*	*		***	**
HUMAN	IIA	<u>NLVNFRHMIK-LTTTGKEAALSYGFYGCCHCGVGGRGSPKDATDR</u>				
RAT	IIA	<u>SLLEFGOMIL-FKTGKRADVSYGFYGCCHCGVGGRGSPKDATDE</u>				
PORCINE	IIA	<u>DLLNERKMIK-LKTGKAPVPNYAFYGCYCGLGGKGSPPKDATD?</u>				
RABBIT	IIA	<u>HLLDERKMIK-YTTTGKEATTSYGAYGCCHCGVGGRGAPK?A</u>				
<hr/>						
Exon 3:		44	50	60	70	80 85
PORCINE	I	<u>CCETHDNCYRDAKNLDSCKFLVDNPTYESYSYSCSNTEITCN</u>				
RAT	I	<u>CCQTHDHCYNQAKKLESCKFLIDNPTYINTYSYKCSGNVITCS</u>				
HUMAN	I	<u>CCQTHDNCYDQAKKLDSCFELLNPNYTHYTSYSCSGSAITCS</u>				
		**				
HUMAN	IIA	<u>CCVTHDCCYKRLEKR-GC-----GTKFLSYKFSSNSGSRITC-</u>				
RAT	IIA	<u>CCVTHECCYNRLEKS-GC-----GTKFLTYKFSSYRGGQISCS</u>				
PORCINE	IIA	<u>CCAAH</u>				
RABBIT	IIA	<u>KFLSYKFESMK</u>				
<hr/>						
Exon: 4		86	90	100	110	120 130
PORCINE	I	<u>SKNNACEAFICNCDRNAAICESKAPYNKEHK-NLDTKKYC</u>				
RAT	I	<u>DKNNDCESEICNCDRQAAICESKVPYNKEYK-DLDTKKHC</u>				
HUMAN	I	<u>SKNKECEAFICNCDRNAAICESKAPYNKAHK-NLDTKKYCQS</u>				
		**				
HUMAN	IIA	<u>AKODSCRSOLCECDKAAATCFARNKTTYNKKYQYYSNKHCRGSTPRC</u>				
RAT	IIA	<u>TNODSCRKQLCOCDKAAAECSRNKKSYSLSKYQFYPNKFCK??TPSC</u>				
RABBIT	IIA	<u>KAAAACE</u> <u>QFYPANRCSGRPPSC</u>				

FIG. 1




FIG. 2a




FIG. 2b




FIG. 2c




FIG. 3a




FIG.3b




FIG. 4a




FIG. 4b




FIG.5

PLA₂ INHIBITORY COMPOUNDS

FIELD OF THE INVENTION

The present invention relates to peptides which inhibit the enzymatic activity of phospholipases A₂ (PLA₂s) and illustrated with peptides which inhibit the activity of Type II PLA₂'s particularly synovial PLA₂ and snake PLA₂ (*Crotalus durissus* and *Crotalus atrox*). In addition, the present invention relates to pharmaceutical composition including, as the active ingredient these peptides and to methods of treatment involving the administration of this composition.

BACKGROUND OF THE INVENTION

Phospholipases A₂ constitute a diverse family of enzymes with two subclasses (Type I and Type II) (FIG. 1), based on the positions of the disulphide bonds in the molecules while bee venom PLA₂ constitutes a third substantially distinct class of PLA₂. X-ray crystallography has revealed that the segments comprising the functional substructure of the enzyme is similar in classes. This similarity is particularly striking when the structurally-related Type I/II enzymes are compared with bee venom enzyme (2). PLA₂ hydrolyses the sn-2 acyl ester bond of phosphoglycerides initiating the release of fatty acid precursors of inflammatory eicosanoids. Human synovial PLA₂ (a Type II molecule) has recently been isolated and identified (3). The same PLA₂ has been implicated in the pathogenesis of several inflammatory diseases in humans such as rheumatoid arthritis and Gram negative septic shock (7;8).

Murine, inhibitory monoclonal antibodies raised against synovial PLA₂ have demonstrated pre-clinical efficacy. Accordingly, there is interest in the development of compositions which inhibit the enzymatic activity of PLA₂.


Tryptic digestion of human synovial PLA₂ and subsequent separation and analysis of the fragments by EPLC gave a very interesting and unexpected result for one of the peaks in that it contained two peptides; one a heptapeptide (the N-terminal peptide) and the other a pentapeptide, FLSYK (SEQ ID NO:8) (corresponding to residues 70-74 in other PLA₂ molecules, based on three-dimensional structural "homology" of mammalian PLA₂ amino acid sequences (1,4)). The pentapeptide was found in an earlier eluting, fully resolved peak (as expected). Since the HPLC system failed to fully resolve these two peptides in the latter peak, these data suggest that the two peptides had a strong affinity for one another and raised questions as to the structural implications of this. X-ray diffraction studies (5,6) have shown that amino acid residues in the two peptides are close to the active site of the enzyme and are important in forming or stabilising the channel in which the 1,2-diacyl-3-sn-phosphoglyceride substrate is precisely positioned for hydrolysis of the 2-ester bond. The first turn of the N-terminal helix (residues 1 to 12) is stabilised by a hydrogen bond network provided by the N-terminus and residue 4, elements of residues 69 to 71 and a water mediated link to the catalytic residues; residues 2 and 5 form the "floor" of the channel, residue 9 forms the right wall and the left wall is formed by residue 69 (either tyrosine or lysine usually) which is predicted to move after the substrate has docked and to form a hydrogen bond with the sn-3 phosphate of the substrate. The chemical evidence of the strong interactions between the heptapeptide and the pentapeptide prompted the supposition that the PLA₂ activity may be inhibited in the presence of either one of these peptides.

Using synthetic peptide chemistry the present inventors have prepared the pentapeptide FLSYK and demonstrated

that addition of it to the assay medium decreased the enzyme activity of human synovial PLA₂ (FIG. 2a). Furthermore, it has been demonstrated that the pentapeptide that occupies the 70-74 region of snake PLA₂ (WDIYR) also inhibited the activity of snake PLA₂ (see FIG. 3b). It is believed that this inhibition is mediated by the peptide binding to the amino terminal end of the enzyme and blocking the reaction either by blocking the substrate access to the hydrophobic channel or by distorting the structure sufficiently to prevent correct orientation of the substrate.

SUMMARY OF THE INVENTION

Accordingly, in a first aspect the present invention consists in a linear or cyclic peptide of at least 5 residues which inhibits the enzymatic activity of human synovial PLA₂, the peptide having the following formula:



in which

A₁ is hydrogen or one or two naturally occurring amino acids

A₂ is F or Y or W or absent

A₃ is L or V or I or M

A₄ is S or T

A₅ is Y or F or W

A₆ is K or R or H or absent


A₇ is OH or one or two naturally occurring amino acids.

In a preferred embodiment the peptide is a pentapeptide.

In another preferred embodiment of the present invention A₁ is H and A₇ is OH.

In a further preferred embodiment of the present invention the peptide is FLSYK (SEQ ID NO:8) or KFLSY (SEQ ID NO:9) and most preferably FLSYK.

In a second aspect the present invention consists in a linear or cyclic peptide of at least 5 residues which inhibits the enzymatic activity of *Crotalus durissus* PLA₂, the peptide having the following formula:



in which

B₁ is hydrogen or one or two naturally occurring amino acids

B₂ is W or F or Y or absent

B₃ is D or E

B₄ is I or V or L or M

B₅ is Y or F or W

B₆ is R or K or H or absent


B₇ is OH or one or two naturally occurring amino acids.

In a preferred embodiment the peptide is a pentapeptide.

In another preferred embodiment of the present invention B₁ is H and B₇ is OH.

In a further preferred embodiment of the present invention the peptide is WDIYR (SEQ ID NO:10).

In a third aspect the present invention consists in a linear or cyclic peptide of at least 5 residues which inhibits the enzymatic activity of *Crotalus atrox* PLA₂, the peptide having the following formula:



in which

C₁ is hydrogen or one or two naturally occurring amino acids

C₂ is T or S or absent

C₃ is V or I or L or M

C₄ is S or T

C₅ is Y or F or W

C₆ is T or S or absent

C₇ is OH or one or two naturally occurring amino acids.

In a preferred embodiment the peptide is a pentapeptide.

In another preferred embodiment of this aspect of the present invention C₁ is H and C₇ is OH.

In a further preferred embodiment of this aspect of the present invention the peptide is TVSYT (SEQ ID NO:11).

As will be clear to those skilled in the art from the disclosure provided herein, the peptides of the first and second aspect of the present invention illustrate how the enzymatic activity of other PLA₂s may be inhibited. This inhibition may be achieved by compounds which interact with the N-terminal amino acid sequence of the PLA₂ molecule in a manner such that the channel into which the phospholipid diffuses prior to catalytic cleavage is destabilized.

Accordingly, in a fourth aspect the present invention consists in a compound which inhibits the enzymatic activity of phospholipase A₂, the compound being characterized in that it interacts with the N-terminal amino acid sequence of the phospholipase A₂ such that the channel into which the phospholipid diffuses prior to catalytic cleavage is either blocked or destabilized.

In a preferred embodiment of the present invention the PLA₂ is human PLA₂ and the compound is a peptide.

In a preferred embodiment of the present invention the peptide has the amino acid sequence FLSYK or KFLSY.

As will be clear to those skilled in the art, the present inventors have found that the enzymatic activity of a phospholipase A₂ can be inhibited by a peptide having a sequence corresponding to a sequence selected from the region of residues 69 to 75 of the phospholipase 2.

Accordingly, in a fifth aspect the present invention consists in a peptide of 5 or 6 residues which inhibits the enzymatic activity of a phospholipase A₂, the peptide having an amino acid sequence corresponding to a sequence selected from the region of residues 69-75 of the phospholipase A₂.

In a preferred embodiment this aspect of the present invention the peptide is a pentapeptide and has an amino acid sequence corresponding to the sequence from residue 69-73 or 70-74 of the phospholipase A₂.

In a further preferred embodiment of the present invention the phospholipase A₂ is human phospholipase A₂.

In a sixth aspect the present invention consists in a composition for use in treating a subject suffering from septic shock rheumatoid arthritis and/or other inflammatory diseases, the composition comprising a therapeutically acceptable amount of peptide or compound of the first, fourth or fifth aspect of the present invention and a pharmaceutical acceptable sterile carrier.

In a seventh aspect the present invention consists in a method of treating septic shock and/or inflammatory disease in a subject comprising administering to the subject the composition of the sixth aspect of the present invention.

It will be appreciated by those skilled in the art that a number of modifications may be made to the peptides of the present invention without deleteriously affecting the biological activity of the peptide. This may be achieved by various changes, such as insertions, deletions and substitutions, either conservative or non-conservative in the peptide sequence where such changes do not substantially decrease

the biological activity of the peptide. By conservative substitutions the intended combinations are:

G, A; V, I, L, M; D, E; N, Q; S, T; K, R, H; and F, Y, W.

It may also be possible to add various groups to the peptide of the present invention to confer advantages such as increased potency or extended half life in vivo, without substantially decreasing the biological activity of the peptide.

It is intended that such modifications to the peptide of the present invention which do not result in a decrease in biological activity are within the scope of the present invention.

DETAILED DESCRIPTION OF THE PRESENT INVENTION

In order that the nature of the present invention may be more clearly understood, preferred forms thereof will now be described with reference to the following examples and Figures, in which:

FIG. 1 shows mammalian PLA₂ amino acid sequences (SEQ ID NOS. 1, 2, 3, 4, 5, 6 and 7).

FIG. 2: Inhibition of human PLA₂ using the peptide FLSYK.

FIG. 2(a) was obtained using a peptide from a tryptic digest of the enzyme (n=7 □ control ♦ inhibitor), 2(b) and 2(c) with a synthetic peptide n=11 □ control ♦ inhibitor

□ control ♦ inhibitor, respectively. The synthetic peptide also inhibits the enzyme in septic shock serum [FIG. 2(c)].

FIG. 3: Dose response curves showing increasing inhibitor with increasing amount of FLSYK and human recombinant Type II PLA₂ (3a □ inhibitor ♦ control) and in PLA₂ in septic shock serum (3b □ inhibitor ♦ control).

FIG. 4: Dose response curves for FLSYK (4a □ PLA₂ ♦ control) and WDIYR (4b □ snake (II) ♦ control) on human PLA₂ and snake (Crotalus Durissus) PLA₂ respectively. Both peptides occupy similar sites in their parent proteins and show inhibitory properties for the enzymatic activity.

FIG. 5 shows a Lineweaver-Buspe plot showing inhibition of PLA₂ by FLSYK (PLA₂ ♦ 10 ug ■ FLSYK, ♦ 1 ug FLSYK).

Inhibition of PLA₂ Activity

Proteins and Peptides

1. Synovial PLA₂, snake PLA₂ (Crotalus Durissus and Crotalus ATR?)
2. Phe-Leu-Ser-Tyr-Lys (FLSYK) (SEQ ID NO:8)
3. Acetyl-Phe-Leu-Ser-Tyr-Lys-Methyl ester (Ac-FLSYK-OMe)
4. Trp-Asp-Ile-Tyr-Arg (WDIYR) (SEQ ID NO:10)
5. Lys-Phe-Leu-Ser-Tyr (KFLSY) (SEQ ID NO:9)
6. Thr-Val-Ser-Tyr-Thr (TVSYT) (SEQ ID NO:12)
7. Phe-Lys-Thr-Tyr-Ser (FKTYS) (SEQ ID NO:13)
8. Thr-Glu-Ser-Tyr-Ser (TESYS) (SEQ ID NO:14)
9. Gly-Thr-Lys-Phe-Leu-Ser-Tyr-Lys-Phe-Ser-Asn (GTKFLSYKPSN) (SEQ ID NO:15)
10. Lys-Phe-Leu-Ser-Tyr-Tyr (KFLSYT) (SEQ ID NO:16)
11. Phe-Leu-Ser-Tyr (FLSY) (SEQ ID NO:17)
12. Phe-Leu-Ser-Tyr-Lys-NH₂ (FLSYK-NH₂)

Tryptic Digestion of PLA₂:

Approximately 100 µg of PLA₂ was dissolved in 300 µl of 1 M Tris pH 8.0 15 µl of Trypsin solution (10µ/1M Tris pH

8) was added and the peptide/trypsin solution was incubated for 2 hours at 37° C. 5 µl of neat TFA was used to lower the pH to terminate the digestion. The whole solution was subjected to microbore HPLC fractionation.

Microbore HPLC fractionation:

An ABI Microbore syringe pump system Model 140 was used. Detector wavelength was set at 220 nm at 0.5 a.u. A RP-300 1×100 mm was used. Fractionation was carried out by running a linear buffer gradient from 0.1% TFA in water to 0.1% TFA, 70% acetonitrile in water over sixty minutes. Amino acid sequences identified from fractions were:

Fraction #2 (K)YQYYSNK

Fraction #4 FLSYK

Fraction #5 FLSYK NLVNFHR

Fraction #7* EALLSYGFY(C)H(C)GVGG(C)(C) VTHD(C)(C)YK SQL(C)E(C)DK IT(C)AK AAAT(C) FAR

* peptides are held together by cystinyl bonds; () denotes tentative assignment.

Fraction #9 EAALSYGFY(C)

Peptide Synthesis:

Peptide synthesis was carried out in an ABI Peptide Synthesiser Model 430A. T-Boc chemistry was used. HF cleavage was used to release peptide from the solid support. PLA₂ Serial Dilution:

Control: 10 µl of a standard PLA₂ solution was used at a concentration of 120 ng/10 µl in 20 mM Tris pH 8. Serial dilution was done by adding 20 mM Tris pH 8 buffer to the final volume of 20 µl.

Inhibitor solution: Pentapeptide was usually dissolved in 1 µl of 0.1% TFA solution and further 9 µl of 20 mM Tris pH8 was added. This solution was always maintained around pH7-8. 10 µl of this inhibitor solution was added into 10 µl of PLA₂ solution. Incubation: all samples were incubated at 37° C. for one hour.

PLA₂ solution: A standard PLA₂ solution was prepared in 20 mM Tris pH8.0 so that 10 µl will give 50% (approx) hydrolysis.

Pentapeptide solution: A standard pentapeptide solution was made to 10 mg/ml in 0.1% TFA. 100 µl was taken out and neutralised with 900 µl 20 mM Tris pH8. 10 µl (10 µg was taken out for dose response together with 10 µl of the PLA₂ solution). Serial dilution was carried out on 10 µl aliquots with 20 mM Tris pH 8.

Septic shock experiments:

Septic shock serum was diluted 1/100 for dose response experiments and used neat for serial dilution. Final reaction volume was always in the ratio of 10 µl serum/10 µl Tris or pentapeptide solution.

Activity assay:

PLA₂ activity was measured using a mixed micelle phosphatidylethanolamine (PE)/sodium deoxycholate assay, modified from a method described by Seilhamer et al (1). The PE substrate was prepared by dissolving freshly desiccated PE (Amersham, Bucks, England) in 2% DOC, then diluting this to 0.22 nmoles PE and 0.04% DOC per sample in assay buffer (50 mM Tris-HCl, pH 8.5, 2 mM calcium chloride, 150 mM sodium chloride, 0.04% DOC). The sample was prepared by mixing 10 µl of the test material with 10 µl mM Tris-HCl pH7.4 and leaving at 37° C. for 10 minutes. The reaction was started by the addition of 25 µl prewarmed substrate and terminated by addition of 10 µl 100 mM EDTA. The reaction mixture (30 µl was spotted and dried on silica TLC plates (Merck, Darmstadt, West Germany), and the plates were chromatographed using chloroform:methanol:acetic acid (90:10:1) as solvent. The dried plates were exposed overnight with Kodak X OMAT AR

film. Radioactivity at the origin and of the liberated arachidonic acid was counted and the percent hydrolysis by PLA₂ determined.

A summary of the results obtained with peptides corresponding to residues 70-74 of several Type I and Type II enzymes are set out in Table 1. These results show that there is considerable species specificity in that peptides active against one species of PLA₂ were not active against the other species tested. In addition none of the peptides tested were active against PLA₂ type 1. This result indicates that inhibition by peptides from this region of PLA₂ (70-74) appears to occur only on type II enzymes.

Peptide 5 was shown to be an active inhibitor of human Type II PLA₂, however peptides 7, 8, 9, 10, 11 and 12 were all formed to be negative. This suggests that the peptide must be of a certain size to show inhibition and that inhibition will occur only with the specific sequence desired from the specific Type II enzyme being tested.

TABLE 1

Type Enzyme Inhibitor	II Syno PLA ₂	II Crot.Dur. PLA ₂	II Crot.Atr. PLA ₂	I N.N.Atra PLA ₂	I Por.Pan PLA ₂
sPLA ₂ (FLSYK)	+	-	-	-	-
Crot.Dur (WDIYR)	-	+	-	-	-
Crot.Atr (TVSYT)	-	-	+	-	-
N.N.Atr (FKTYS)	-	-	-	-	-
Por.Pan (TESYS)	-	-	-	-	-
sPLA ₂ - Human Type II PLA ₂					
Crot.Dur- <i>Crotalus decrissus</i> PLA ₂					
Crot.Atr- <i>Crotalus atrox</i> PLA ₂					
N.N.Atr- <i>Naja naja atrox</i> PLA ₂					
Por.Pan- Porcine pancreatic PLA ₂					

From the above results the present inventors believe that short peptides from the 70-74th region will most likely compete with the substrate for access to the active site and give inhibitory effects. It is believed that variation of the length of the peptides present in these regions may result in an optimisation of the inhibition.

The pentapeptide apparently possesses helical structure (approximately one and a half turns). Since the helical structures are stabilised by hydrogen bonds between the C=O of one residue and NH of the fourth residue along the chain, the structure of the pentapeptide may be somewhat unstable and be more sensitive to the environment than a longer helical molecule. On the other hand, it would be expected that the range of sizes that is effective will be limited because of the limited access to the active site of PLA₂.

It is believed that the usual interchange of a hydrophobic residue e.g. Leu to Ile, Ser to Thr could also maintain the inhibitory effect. That is, amino acid residues alike in either charge or hydrophobicity could possibly be interchanged with those in the models without destroying the specific interaction of the two regions. Since helix-helix interactions are possibly the cause of the inhibitory action, small increases in the length of the peptides could stabilise this structure.

The results obtained in these studies also suggest that monoclonal antibodies could be raised against epitopes containing one or both of the peptide regions to effect a similar result on the PLA₂ activity. Such monoclonal antibodies could be produced using standard techniques well known in the art.

As will be apparent to those skilled in the art the principle of the present invention will also have application for the inhibition of the activity of enzymes other than PLA₂ eg. the neuraminidase enzyme of the influenza virus or neuropeptide Y. It is envisaged that as biological active proteins in general, possess an active conformation which is stabilized by interaction with the surrounding chain of amino acids, that peptides adjacent to, and capable of interaction with the residues within the active site will inhibit the activity of the enzyme. It is intended that such other peptides are included within the scope of the present invention.

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly

described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

REFERENCES

1. Johnson L. K. et al, Advance in Exp. Med & Biol; PLA 2 Role and Function in Inflammation, P. Y-K Wong ed, Plenum Press 17-34 (1991).
2. Scott D. L. et al, Science 250, 1563 (1990).
3. Seilhamer J. J. et al, J. Biol Chem 264, 5335 (1989).
4. Renetseder R. et al, J. Biol Chem 260, 11627 (1985)
5. Scott D. L. et al, Science 250, 1541 (1990).
6. White S. P. et al, Science 250, 1560 (1990).
7. Prozanski W. et al, J. Rheumatol., 15:1351-1355 (1988)
8. Vadas P., J. Lab. Clin. Med., 104:873-881 (1984)

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i i i) NUMBER OF SEQUENCES: 17

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 124 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: protein

(i i i) HYPOTHETICAL: NO

(i v) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Ala	Leu	Trp	Gln	Phe	Arg	Ser	Met	Ile	Lys	Cys	Ala	Ile	Pro	Gly	Ser	1	5	10	15
His	Pro	Leu	Met	Asp	Phe	Asn	Asn	Tyr	Gly	Cys	Tyr	Cys	Gly	Leu	Gly	20	25	30	
Gly	Ser	Gly	Thr	Pro	Val	Asp	Glu	Leu	Asp	Arg	Cys	Cys	Glu	Thr	His	35	40	45	
Asp	Asn	Cys	Tyr	Arg	Asp	Ala	Lys	Asn	Leu	Asp	Ser	Cys	Lys	Phe	Leu	50	55	60	
Val	Asp	Asn	Pro	Tyr	Thr	Glu	Ser	Tyr	Ser	Tyr	Ser	Cys	Ser	Asn	Thr	65	70	75	80
Glu	Ile	Thr	Cys	Asn	Ser	Lys	Asn	Asn	Ala	Cys	Glu	Ala	Phe	Ile	Cys	85	90	95	
Asn	Cys	Asp	Arg	Asa	Ala	Ala	Ile	Cys	Phe	Ser	Lys	Ala	Pro	Tyr	Asn	100	105	110	
Lys	Glu	His	Lys	Asn	Leu	Asp	Thr	Lys	Lys	Tyr	Cys					115	120		

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 124 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: protein

-continued

(i i i) HYPOTHETICAL: NO

(i v) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Ala	Val	Trp	Gln	Phe	Arg	Asn	Met	Ile	Lys	Cys	Thr	Ile	Pro	Gly	Ser	1	5	10	15
Asp	Pro	Phe	Arg	Glu	Tyr	Asn	Asn	Tyr	Gly	Cys	Tyr	Cys	Gly	Leu	Gly	20	25	30	
Gly	Ser	Gly	Thr	Pro	Val	Asp	Asp	Leu	Asp	Arg	Cys	Cys	Gln	Thr	His	35	40	45	
Asp	His	Cys	Tyr	Asn	Gln	Ala	Lys	Lys	Leu	Glu	Ser	Cys	Lys	Phe	Leu	50	55	60	
Ile	Asp	Asn	Pro	Tyr	Thr	Asn	Thr	Tyr	Ser	Tyr	Lys	Cys	Ser	Gly	Asn	65	70	75	80
Val	Ile	Thr	Cys	Ser	Asp	Lys	Asn	Asn	Asp	Cys	Glu	Ser	Phe	Ile	Cys	85	90	95	
Asn	Cys	Asp	Arg	Gln	Ala	Ala	Ile	Cys	Phe	Ser	Lys	Val	Pro	Tyr	Asn	100	105	110	
Lys	Glu	Tyr	Lys	Asp	Leu	Asp	Thr	Lys	Lys	His	Cys	115	120						

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 126 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: protein

(i i i) HYPOTHETICAL: NO

(i v) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Ala	Val	Trp	Gln	Phe	Arg	Lys	Met	Ile	Lys	Cys	Val	Ile	Pro	Gly	Ser	1	5	10	15
Asp	Pro	Phe	Leu	Glu	Tyr	Asn	Asn	Tyr	Gly	Cys	Tyr	Cys	Gly	Leu	Gly	20	25	30	
Gly	Ser	Gly	Thr	Pro	Val	Asp	Glu	Leu	Asp	Lys	Cys	Cys	Gln	Thr	His	35	40	45	
Asp	Asn	Cys	Tyr	Asp	Gln	Ala	Lys	Lys	Leu	Asp	Ser	Cys	Lys	Phe	Leu	50	55	60	
Leu	Asp	Asn	Pro	Tyr	Thr	His	Thr	Tyr	Ser	Tyr	Ser	Cys	Ser	Gly	Ser	65	70	75	80
Ala	Ile	Thr	Cys	Ser	Ser	Lys	Asn	Lys	Glu	Cys	Glu	Ala	Phe	Ile	Cys	85	90	95	
Asn	Cys	Asp	Arg	Asn	Ala	Ala	Ile	Cys	Phe	Ser	Lys	Ala	Pro	Tyr	Asn	100	105	110	
Lys	Ala	His	Lys	Asn	Leu	Asp	Thr	Lys	Lys	Tyr	Cys	Gln	Ser	115	120	125			

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

-continued

(A) LENGTH: 124 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: protein

(i i i) HYPOTHETICAL: NO

(i v) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Asn	Leu	Val	Asn	Phe	His	Arg	Met	Ile	Lys	Leu	Thr	Thr	Gly	Lys	Glu
1				5					10					15	
Ala	Ala	Leu	Ser	Tyr	Gly	Phe	Tyr	Gly	Cys	His	Cys	Gly	Val	Gly	Gly
			20					25					30		
Arg	Gly	Ser	Pro	Lys	Asp	Ala	Thr	Asp	Arg	Cys	Cys	Val	Thr	His	Asp
		35					40					45			
Cys	Cys	Tyr	Lys	Arg	Leu	Glu	Lys	Arg	Gly	Cys	Gly	Thr	Lys	Phe	Leu
	50					55					60				
Ser	Tyr	Lys	Phe	Ser	Asn	Ser	Gly	Ser	Arg	Ile	Thr	Cys	Ala	Lys	Gln
65					70					75					80
Asp	Ser	Cys	Arg	Ser	Gln	Leu	Cys	Glu	Cys	Asp	Lys	Ala	Ala	Ala	Thr
				85					90					95	
Cys	Phe	Ala	Arg	Asn	Lys	Thr	Thr	Tyr	Asn	Lys	Lys	Tyr	Gln	Tyr	Tyr
			100					105					110		
Ser	Asn	Lys	His	Cys	Arg	Gly	Ser	Thr	Pro	Arg	Cys				
		115					120								

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 125 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: protein

(i i i) HYPOTHETICAL: NO

(i v) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Ser	Leu	Leu	Glu	Phe	Gly	Gln	Met	Ile	Leu	Phe	Lys	Thr	Gly	Lys	Arg
1				5					10					15	
Ala	Asp	Val	Ser	Tyr	Gly	Phe	Tyr	Gly	Cys	His	Cys	Gly	Val	Gly	Gly
			20					25					30		
Arg	Gly	Ser	Pro	Lys	Asp	Ala	Thr	Asp	Glu	Cys	Cys	Val	Thr	His	Glu
		35					40					45			
Cys	Cys	Tyr	Asn	Arg	Leu	Glu	Lys	Ser	Gly	Cys	Gly	Thr	Lys	Phe	Leu
	50					55					60				
Thr	Tyr	Lys	Phe	Ser	Tyr	Arg	Gly	Gly	Gln	Ile	Ser	Cys	Ser	Thr	Asn
65					70				75						80
Gln	Asp	Ser	Cys	Arg	Lys	Gln	Leu	Cys	Gln	Cys	Asp	Lys	Ala	Ala	Ala
				85					90					95	
Glu	Cys	Phe	Ser	Arg	Asn	Lys	Lys	Ser	Tyr	Ser	Leu	Lys	Tyr	Gln	Phe
			100					105					110		
Tyr	Pro	Asn	Lys	Phe	Cys	Lys	Xaa	Xaa	Thr	Pro	Ser	Cys			

-continued

115

120

125

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 47 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: protein

(i i i) HYPOTHETICAL: NO

(i v) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

Asp  Leu  Leu  Asn  Phe  Arg  Lys  Met  Ile  Lys  Leu  Lys  Thr  Gly  Lys  Ala
 1              5              10              15
Pro  Val  Pro  Asn  Tyr  Ala  Phe  Tyr  Gly  Cys  Tyr  Cys  Gly  Leu  Gly  Gly
              20              25              30
Lys  Gly  Ser  Pro  Lys  Asp  Ala  Thr  Asp  Xaa  Cys  Cys  Ala  Ala  His
      35              40              45

```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 71 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: protein

(i i i) HYPOTHETICAL: NO

(i v) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

His  Leu  Leu  Asp  Phe  Arg  Lys  Met  Ile  Arg  Tyr  Thr  Thr  Gly  Lys  Glu
 1              5              10              15
Ala  Thr  Thr  Ser  Tyr  Gly  Ala  Tyr  Gly  Cys  His  Cys  Gly  Val  Gly  Gly
              20              25              30
Arg  Gly  Ala  Pro  Lys  Xaa  Ala  Lys  Phe  Leu  Ser  Tyr  Lys  Phe  Ser  Met
      35              40              45
Lys  Lys  Ala  Ala  Ala  Ala  Cys  Phe  Gln  Phe  Tyr  Pro  Ala  Asn  Arg  Cys
      50              55              60
Ser  Gly  Arg  Pro  Pro  Ser  Cys
      65              70

```

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: both

(i i) MOLECULE TYPE: peptide

(i i i) HYPOTHETICAL: NO

(i v) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

-continued

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:8:

P h e L e u S e r T y r L y s
1 5

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both

(i i) MOLECULE TYPE: peptide

(i i i) HYPOTHETICAL: NO

(i v) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:9:

L y s P h e L e u S e r T y r
1 5

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both

(i i) MOLECULE TYPE: peptide

(i i i) HYPOTHETICAL: NO

(i v) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:10:

T r p A s p I l e T y r A r g
1 5

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both

(i i) MOLECULE TYPE: peptide

(i i i) HYPOTHETICAL: NO

(i v) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:11:

T h r V a l S e r T y r T h r
1 5

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both

-continued

(i i) MOLECULE TYPE: peptide
(i i i) HYPOTHEETICAL: NO
(i v) ANTI-SENSE: NO
(v) FRAGMENT TYPE: N-terminal
(x i) SEQUENCE DESCRIPTION: SEQ ID NO:12:
Thr Val Ser Thr Thr
1 5

(2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both
(i i) MOLECULE TYPE: peptide
(i i i) HYPOTHEETICAL: NO
(i v) ANTI-SENSE: NO
(v) FRAGMENT TYPE: N-terminal
(x i) SEQUENCE DESCRIPTION: SEQ ID NO:13:
Phe Lys Thr Tyr Ser
1 5

(2) INFORMATION FOR SEQ ID NO:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both
(i i) MOLECULE TYPE: peptide
(i i i) HYPOTHEETICAL: NO
(i v) ANTI-SENSE: NO
(v) FRAGMENT TYPE: N-terminal
(x i) SEQUENCE DESCRIPTION: SEQ ID NO:14:
Thr Glu Ser Tyr Ser
1 5

(2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both
(i i) MOLECULE TYPE: peptide
(i i i) HYPOTHEETICAL: NO
(i v) ANTI-SENSE: NO
(v) FRAGMENT TYPE: N-terminal
(x i) SEQUENCE DESCRIPTION: SEQ ID NO:15:
Gly Thr Lys Phe Leu Ser Tyr Lys Phe Ser Asn
1 5 10

-continued

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 6 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: both

(i i) MOLECULE TYPE: peptide

(i i i) HYPOTHETICAL: NO

(i v) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Lys Phe Leu Ser Tyr Tyr
 1 5

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 4 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: both

(i i) MOLECULE TYPE: peptide

(i i i) HYPOTHETICAL: NO

(i v) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Phe Leu Ser Tyr
 1

We claim:

1. A linear or cyclic peptide of at least 5 residues which inhibits the enzymatic activity of human synovial PLA₂, the peptide having the following formula:



in which

A₁ is K or R or H or absentA₂ is F or Y or WA₃ is L or V or I or MA₄ is S or TA₅ is Y or F or WA₆ is K or R or H or absent.

2. A peptide as claimed in claim 1 in which the peptide is FLSYK or KFLSY.

3. A peptide as claimed in claim 1 in which the phospholipase A₂ is human phospholipase A₂.

4. A composition for use in treating the subject suffering from rheumatoid arthritis, septic shock and/or inflammatory disease, the composition comprising a therapeutically effective amount of the peptide as claimed in claim 1 and a pharmaceutically acceptable sterile carrier.

5. A peptide as claimed in claim 1, in which either A₁ or A₆ is absent.

6. A linear peptide which inhibits the enzymatic activity of *Crotalus durissus* PLA₂, the peptide having the following formula:




in which

B₂ is W or F or YB₃ is D or EB₄ is I or V or L or MB₅ is Y or F or WB₆ is R or K or H.

7. A peptide as claimed in claim 6 in which the peptide is WDIYR.

8. A linear peptide which inhibits the enzymatic activity of *Crotalus atrox* PLA₂, the peptide having the following formula:



in which

C₂ is T or SC₃ is V or I or L or MC₄ is T or SC₅ is Y or F or WC₆ is T or S.

9. A peptide as claimed in claim 8 in which the peptide is TVSYT.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 5,656,602

DATED : August 12, 1997

INVENTOR(S) : Albert Peng Sheng Tseng et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the title page, item [54] and column 1, line 1, the title should be
--PLA2 INHIBITORY COMPOUNDS--.

In the Claims:

Col. 19, line 41 (claim 1), "or cyclic" should be deleted.

Signed and Sealed this
Fourteenth Day of April, 1998



Attest:

BRUCE LEHMAN

Attesting Officer

Commissioner of Patents and Trademarks